Estrogen regulates tumor growth through a nonclassical pathway that includes the transcription factors ERβ and KLF5

Science Signaling

Volumn 4, Issue 168, 2011, Pages

  Nakajima, Yuka ^a   Akaogi, Kensuke ^a   Suzuki, Takashi ^b   Osakabe, Asami ^a   Yamaguchi, Chie ^a   Sunahara, Nanae ^a   Ishida, Junji ^a   Kako, Koichiro ^a   Ogawa, Sonoko ^a   Fujimura, Tetsuya ^c   Homma, Yukio ^c   Fukamizu, Akiyoshi ^a   Murayama, Akiko ^a,d   Kimura, Keiji ^a   Inoue, Satoshi ^c,e   Yanagisawa, Junn ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (6 METHYL 1,3 BENZOTHIAZOL 2 YL)PHENOL; ANTIESTROGEN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; ESTROGEN; ESTROGEN RECEPTOR BETA; FULVESTRANT; KRUPPEL LIKE FACTOR 5; PHENOL DERIVATIVE; TRANSCRIPTION FACTOR FKHR; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; ESTRADIOL; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; KLF5 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOIKIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; ESTROGEN ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN DEGRADATION; TUMOR GROWTH; UBIQUITINATION; ANIMAL; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOBLOTTING; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR VOLUME;

AGED; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL LINE, TUMOR; CELL PROLIFERATION; CREB-BINDING PROTEIN; ESTRADIOL; ESTROGEN RECEPTOR BETA; ESTROGENS; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MICE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79954557105     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2001551     Document Type: Article

References (66)

1. J. T. Isaacs, W. B. Isaacs, Androgen receptor outwits prostate cancer drugs. Nat. Med. 10, 26-27 (2004).
2. B. Schmitt, T. J. Wilt, P. F. Schellhammer, V. DeMasi, O. Sartor, E. D. Crawford, C. L. Bennett, Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: A systematic review. Urology 57, 727-732 (2001).
3. D. P. Petrylak, C. M. Tangen, M. H. Hussain, P. N. Lara Jr., J. A. Jones, M. E. Taplin, P. A. Burch, D. Berry, C. Moinpour, M. Kohli, M. C. Benson, E. J. Small, D. Raghavan, E. D. Crawford, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513-1520 (2004).
4. E. S. Antonarakis, C. G. Drake, Current status of immunological therapies for prostate cancer. Curr. Opin. Urol. 20, 241-246 (2010).
5. K. N. Chi, A. Bjartell, D. Dearnaley, F. Saad, F. H. Schröder, C. Sternberg, B. Tombal, T. Visakorpi, Castration-resistant prostate cancer: From new pathophysiology to new treatment targets. Eur. Urol. 56, 594-605 (2009).
6. A. L. Harzstark, E. J. Small, Castrate-resistant prostate cancer: Therapeutic strategies. Expert Opin. Pharmacother. 11, 937-945 (2010).
7. N. Burns-Cox, V. Basketter, B. Higgins, S. Holmes, Prospective randomised trial comparing diethylstilboestrol and flutamide in the treatment of hormone relapsed prostate cancer. Int. J. Urol. 9, 431-434 (2002).
8. P. L. Härkönen, S. I. Mäkelä, Role of estrogens in development of prostate cancer. J. Steroid Biochem. Mol. Biol. 92, 297-305 (2004).
9. G. S. Prins, K. S. Korach, The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 73, 233-244 (2008).
10. P. B. Singh, S. S. Matanhelia, F. L. Martin, A potential paradox in prostate adenocarcinoma progression: Oestrogen as the initiating driver. Eur. J. Cancer 44, 928-936 (2008).
11. M. C. Bosland, The role of estrogens in prostate carcinogenesis: A rationale for chemoprevention. Rev. Urol. 7 (Suppl. 3), S4-S10 (2005).
12. S. M. Ho, Estrogens and anti-estrogens: Key mediators of prostate carcinogenesis and new therapeutic candidates. J. Cell. Biochem. 91, 491-503 (2004).
13. G. P. Risbridger, J. J. Bianco, S. J. Ellem, S. J. McPherson, Oestrogens and prostate cancer. Endocr. Relat. Cancer 10, 187-191 (2003).
14. M. S. Steiner, S. Raghow, Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk. World J. Urol. 21, 31-36 (2003).
15. K. M. Lau, M. LaSpina, J. Long, S. M. Ho, Expression of estrogen receptor (ER)-α and ER-β in normal and malignant prostatic epithelial cells: Regulation by methylation and involvement in growth regulation. Cancer Res. 60, 3175-3182 (2000).
16. I. Y. Kim, B. C. Kim, D. H. Seong, D. K. Lee, J. M. Seo, Y. J. Hong, H. T. Kim, R. A. Morton, S. J. Kim, Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Res. 62, 5365-5369 (2002).
17. J. M. Blesa, V. A. Candel, PSA decrease with fulvestrant acetate in a hormone-resistant metastatic prostate cancer patient. Onkologie 33, 57-59 (2010).
18. B. J. Cheskis, J. G. Greger, S. Nagpal, L. P. Freedman, Signaling by estrogens. J. Cell. Physiol. 213, 610-617 (2007).
19. R. L. Shazer, A. Jain, A. V. Galkin, N. Cinman, K. N. Nguyen, R. B. Natale, M. Gross, L. Green, L. I. Bender, S. Holden, L. Kaplan, D. B. Agus, Raloxifene, an oestrogen-receptor- β-targeted therapy, inhibits androgen-independent prostate cancer growth: Results from preclinical studies and a pilot phase II clinical trial. BJU Int. 97, 691-697 (2006).
20. A. Morani, M. Warner, J. A. Gustafsson, Biological functions and clinical implications of oestrogen receptors α and β in epithelial tissues. J. Intern. Med. 264, 128-142 (2008).
21. V. C. Jordan, B. W. O'Malley, Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J. Clin. Oncol. 25, 5815-5824 (2007).
22. W. Shao, M. Brown, Advances in estrogen receptor biology: Prospects for improvements in targeted breast cancer therapy. Breast Cancer Res. 6, 39-52 (2004).
23. D. J. Mangelsdorf, C. Thummel, M. Beato, P. Herrlich, G. Schütz, K. Umesono, B. Blumberg, P. Kastner, M. Mark, P. Chambon, R. M. Evans, The nuclear receptor superfamily: The second decade. Cell 83, 835-839 (1995).
24. E. Enmark, M. Pelto-Huikko, K. Grandien, S. Lagercrantz, J. Lagercrantz, G. Fried, M. Nordenskjöld, J. A. Gustafsson, Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern. J. Clin. Endocrinol. Metab. 82, 4258-4265 (1997).
25. S. Mosselman, L. H. Looijenga, A. J. Gillis, M. A. van Rooijen, H. J. Kraft, E. J. van Zoelen, J. W. Oosterhuis, Aberrant platelet-derived growth factor α-receptor transcript as a diagnostic marker for early human germ cell tumors of the adult testis. Proc. Natl. Acad. Sci. U.S.A. 93, 2884-2888 (1996).
26. L. G. Horvath, S. M. Henshall, C. S. Lee, D. R. Head, D. I. Quinn, S. Makela, W. Delprado, D. Golovsky, P. C. Brenner, G. O'Neill, R. Kooner, P. D. Stricker, J. J. Grygiel, J. A. Gustafsson, R. L. Sutherland, Frequent loss of estrogen receptor-β expression in prostate cancer. Cancer Res. 61, 5331-5335 (2001).
27. I. Leav, K. M. Lau, J. Y. Adams, J. E. McNeal, M. E. Taplin, J. Wang, H. Singh, S. M. Ho, Comparative studies of the estrogen receptors β and α and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am. J. Pathol. 159, 79-92 (2001).
28. D. Pasquali, V. Rossi, D. Esposito, C. Abbondanza, G. A. Puca, A. Bellastella, A. A. Sinisi, Loss of estrogen receptor β expression in malignant human prostate cells in primary cultures and in prostate cancer tissues. J. Clin. Endocrinol. Metab. 86, 2051-2055 (2001).
29. Z. Weihua, M. Warner, J. A. Gustafsson, Estrogen receptor β in the prostate. Mol. Cell. Endocrinol. 193, 1-5 (2002).
30. D. T. Dang, J. Pevsner, V. W. Yang, The biology of the mammalian Krüppel-like family of transcription factors. Int. J. Biochem. Cell Biol. 32, 1103-1121 (2000).
31. C. Chen, W. W. Brabham, B. G. Stultz, H. F. Frierson Jr., J. C. Barrett, C. L. Sawyers, J. T. Isaacs, J. T. Dong, Defining a common region of deletion at 13q21 in human cancers. Genes Chromosomes Cancer 31, 333-344 (2001).
32. C. Chen, H. V. Bhalala, R. L. Vessella, J. T. Dong, KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer. Prostate 55, 81-88 (2003).
33. Y. Oishi, I. Manabe, K. Tobe, M. Ohsugi, T. Kubota, K. Fujiu, K. Maemura, N. Kubota, T. Kadowaki, R. Nagai, SUMOylation of Krüppel-like transcription factor 5 acts as a molecular switch in transcriptional programs of lipid metabolism involving PPAR-δ. Nat. Med. 14, 656-666 (2008).
34. A. R. Black, J. D. Black, J. Azizkhan-Clifford, Sp1 and krüppel-like factor family of transcription factors in cell growth regulation and cancer. J. Cell. Physiol. 188, 143-160 (2001).
35. Min mutation in the intestine. Cancer Res. 69, 4125-4133 (2009).
36. T. Shindo, I. Manabe, Y. Fukushima, K. Tobe, K. Aizawa, S. Miyamoto, K. Kawai-Kowase, N. Moriyama, Y. Imai, H. Kawakami, H. Nishimatsu, T. Ishikawa, T. Suzuki, H. Morita, K. Maemura, M. Sata, Y. Hirata, M. Komukai, H. Kagechika, T. Kadowaki, M. Kurabayashi, R. Nagai, Krüppel-like zinc-finger transcription factorKLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat. Med. 8, 856-863 (2002).
37. M. O. Nandan, B. B. McConnell, A. M. Ghaleb, A. B. Bialkowska, H. Sheng, J. Shao, B. A. Babbin, S. Robine, V. W. Yang, Krüppel-like factor 5 mediates cellular transformation during oncogenicKRAS-induced intestinal tumorigenesis. Gastroenterology 134, 120-130 (2008).
38. B. B. McConnell, A. M. Ghaleb, M. O. Nandan, V. W. Yang, The diverse functions of Krüppel-like factors 4 and 5 in epithelial biology and pathobiology. Bioessays 29, 549-557 (2007).
39. H. Zhang, A. Bialkowska, R. Rusovici, S. Chanchevalap, H. Shim, J. P. Katz, V. W. Yang, C. C. Yun, Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of Krüppel-like factor 5. J. Biol. Chem. 282, 15541-15549 (2007).
40. S. Chanchevalap, M. O. Nandan, D. Merlin, V. W. Yang, All-trans retinoic acid inhibits proliferation of intestinal epithelial cells by inhibiting expression of the gene encoding Krüppel-like factor 5. FEBS Lett. 578, 99-105 (2004).
41. R. Sun, X. Chen, V. W. Yang, Intestinal-enriched Krüppel-like factor (Krüppel-like factor 5) is a positive regulator of cellular proliferation. J. Biol. Chem. 276, 6897-6900 (2001).
42. N. W. Bateman, D. Tan, R. G. Pestell, J. D. Black, A. R. Black, Intestinal tumor progression is associated with altered function of KLF5. J. Biol. Chem. 279, 12093-12101 (2004).
43. C. Chen, H. V. Bhalala, H. Qiao, J. T. Dong, A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene 21, 6567-6572 (2002).
44. C. Chen, X. Sun, P. Guo, X. Y. Dong, P. Sethi, X. Cheng, J. Zhou, J. Ling, J. W. Simons, J. B. Lingrel, J. T. Dong, Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells. J. Biol. Chem. 280, 41553-41561 (2005).
45. C. Chen, Z. Zhou, P. Guo, J. T. Dong, Proteasomal degradation of the KLF5 transcription factor through a ubiquitin-independent pathway. FEBS Lett. 581, 1124-1130 (2007).
46. T. Fujimura, S. Takahashi, T. Urano, S. Ogawa, Y. Ouchi, T. Kitamura, M. Muramatsu, S. Inoue, Differential expression of estrogen receptor β (ERβ) and its C-terminal truncated splice variant ERβcx as prognostic predictors in human prostatic cancer. Biochem. Biophys. Res. Commun. 289, 692-699 (2001).
47. L. Björnström, M. Sjöberg, Mechanisms of estrogen receptor signaling: Convergence of genomic and nongenomic actions on target genes. Mol. Endocrinol. 19, 833-842 (2005).
48. R. Nagai, T. Suzuki, K. Aizawa, T. Shindo, I. Manabe, Significance of the transcription factor KLF5 in cardiovascular remodeling. J. Thromb. Haemost. 3, 1569-1576 (2005).
49. J. T. Dong, Prevalent mutations in prostate cancer. J. Cell. Biochem. 97, 433-447 (2006).
50. T. B. Dansen, B. M. Burgering, Unravelling the tumor-suppressive functions of FOXO proteins. Trends Cell Biol. 18, 421-429 (2008).
51. V. Modur, R. Nagarajan, B. M. Evers, J. Milbrandt, FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J. Biol. Chem. 277, 47928-47937 (2002).
52. E. R. Prossnitz, L. A. Sklar, T. I. Oprea, J. B. Arterburn, GPR30: A novel therapeutic target in estrogen-related disease. Trends Pharmacol. Sci. 29, 116-123 (2008).
53. 2 cell-cycle arrest. Cell Death Differ. 17, 1511-1523 (2010).
54. T. Fixemer, K. Remberger, H. Bonkhoff, Differential expression of the estrogen receptor β (ERβ) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 54, 79-87 (2003).
55. K. Nowak, K. Killmer, C. Gessner, W. Lutz, E2F-1 regulates expression of FOXO1 and FOXO3a. Biochim. Biophys. Acta 1769, 244-252 (2007).
56. R. J. Davis, J. L. Bennicelli, R. A. Macina, L. M. Nycum, J. A. Biegel, F. G. Barr, Structural characterization of the FKHR gene and its rearrangement in alveolar rhabdomyosarcoma. Hum. Mol. Genet. 4, 2355-2362 (1995).
57. V. C. Jordan, Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat. Rev. Cancer 7, 46-53 (2007).
58. C. A. Cornil, G. F. Ball, J. Balthazart, Functional significance of the rapid regulation of brain estrogen action: Where do the estrogens come from? Brain Res. 1126, 2-26 (2006).
59. X. Zhu, I. Leav, Y. K. Leung, M. Wu, Q. Liu, Y. Gao, J. E. McNeal, S. M. Ho, Dynamic regulation of estrogen receptor-β expression by DNA methylation during prostate cancer development and metastasis. Am. J. Pathol. 164, 2003-2012 (2004).
60. J. Cheng, E. J. Lee, L. D. Madison, G. Lazennec, Expression of estrogen receptor β in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett. 566, 169-172 (2004).
61. J. S. Lai, L. G. Brown, L. D. True, S. J. Hawley, R. B. Etzioni, C. S. Higano, S. M. Ho, R. L. Vessella, E. Corey, Metastases of prostate cancer express estrogen receptor-β. Urology 64, 814-820 (2004).
62. Y. K. Leung, Y. Gao, K. M. Lau, X. Zhang, S. M. Ho, ICI 182,780-regulated gene expression in DU145 prostate cancer cells is mediated by estrogen receptor-β/NFκB crosstalk. Neoplasia 8, 242-249 (2006).
63. A. Vermeulen, J. M. Kaufman, S. Goemaere, I. van Pottelberg, Estradiol in elderly men. Aging Male 5, 98-102 (2002).
64. Y. Tateishi, R. Sonoo, Y. Sekiya, N. Sunahara, M. Kawano, M. Wayama, R. Hirota, Y. Kawabe, A. Murayama, S. Kato, K. Kimura, J. Yanagisawa, Turning off estrogen receptor β-mediated transcription requires estrogen-dependent receptor proteolysis. Mol. Cell. Biol. 26, 7966-7976 (2006).
65. M. Kajiro, R. Hirota, Y. Nakajima, K. Kawanowa, K. So-ma, I. Ito, Y. Yamaguchi, S. H. Ohie, Y. Kobayashi, Y. Seino, M. Kawano, Y. Kawabe, H. Takei, S. Hayashi, M. Kurosumi, A. Murayama, K. Kimura, J. Yanagisawa, The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways. Nat. Cell Biol. 11, 312-319 (2009).
66. Acknowledgments: We thank N. Ohnuma for valuable discussions and technical advice. Funding: This work was supported by the Targeted Proteins Research Program (J.Y.), the Program for Promotion of Fundamental Studies in Health Sciences (J.Y. and S.I.) from the National Institute of Biomedical Innovation, and Cell Innovation Program (S.I.), the Ministry of Education, Culture, Sports, Science and Technology of Japan. Author contributions: Y.N. and K.A. conceived and designed the experiments and analyzed the data with significant assistance from J.I., K. Kako, S.O., A.F., and K. Kimura; T.S., T.F., Y.H., and S.I. analyzed the human tissue samples; A.O. and C.Y. contributed to the animal experiments; N.S. and A.M. performed the in vitro experiments; S.I. and J.Y. wrote the manuscript. Competing interests: The authors declare that they have no competing interests.